Naoki Furuya, MD, PhD, of the St. Marianna University School of Medicine, discusses phase III study findings on a comparison of bevacizumab plus erlotinib to erlotinib in patients with untreated non–small cell lung cancer with activating EGFR mutations (Abstract 9006).
Juliet Elizabeth Wolford, MD, of the University of California, Irvine, discusses the cost-effectiveness of various types of maintenance therapy in advanced ovarian cancer: paclitaxel, bevacizumab, niraparib, rucaparib, olaparib, and pembrolizumab (Abstract 5508).
Supriya G. Mohile, MD, of the University of Rochester Medical Center, discusses study findings on ways to improve communication with older cancer patients using geriatric assessment (Abstract LBA10003).
Gianni Bisogno, MD, of the University Hospital of Padova, discusses study findings on maintenance low-dose chemotherapy in patients with high-risk rhabdomyosarcoma (Abstract LBA2).
Peter Schmid, MD, PhD, of Queen Mary University of London, discusses phase II study findings on AZD5363 plus paclitaxel vs placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (Abstract 1007).
Lee S. Schwartzberg, MD, of West Cancer Center, reports on the progress of the ACCC Immuno-Oncology Institute to speed adoption of immunotherapeutics in community practices.
